Cargando…

Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection

INTRODUCTION: Previous studies reported the beneficial effects of pretreatment with melatonin on the heart during cardiac ischemia/reperfusion (I/R) injury. However, the effects of melatonin given after cardiac ischemia, as well as its comparative temporal effects are unknown. These include pretreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhanat, Kodchanan, Apaijai, Nattayaporn, Jaiwongkam, Thidarat, Kerdphoo, Sasiwan, Chattipakorn, Siriporn C., Chattipakorn, Nipon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020169/
https://www.ncbi.nlm.nih.gov/pubmed/33842003
http://dx.doi.org/10.1016/j.jare.2020.09.007
_version_ 1783674530173026304
author Singhanat, Kodchanan
Apaijai, Nattayaporn
Jaiwongkam, Thidarat
Kerdphoo, Sasiwan
Chattipakorn, Siriporn C.
Chattipakorn, Nipon
author_facet Singhanat, Kodchanan
Apaijai, Nattayaporn
Jaiwongkam, Thidarat
Kerdphoo, Sasiwan
Chattipakorn, Siriporn C.
Chattipakorn, Nipon
author_sort Singhanat, Kodchanan
collection PubMed
description INTRODUCTION: Previous studies reported the beneficial effects of pretreatment with melatonin on the heart during cardiac ischemia/reperfusion (I/R) injury. However, the effects of melatonin given after cardiac ischemia, as well as its comparative temporal effects are unknown. These include pretreatment, during ischemia, and at the onset of reperfusion. Also, the association between melatonin receptors and cardiac arrhythmias, mitochondrial function and dynamics, autophagy, and mitophagy during cardiac I/R have not been investigated. OBJECTIVES: We tested two major hypotheses in this study. Firstly, the temporal effect of melatonin administration exerts different cardioprotective efficacy during cardiac I/R. Secondly, melatonin provides cardioprotective effects via MT2 activation, leading to improvement in cardiac mitochondrial function and dynamics, reduced excessive mitophagy and autophagy, and decreased cardiac arrhythmias, resulting in improved LV function. METHODS: Male rats were subjected to cardiac I/R, and divided into 4 intervention groups: vehicle, pretreatment with melatonin, melatonin given during ischemia, and melatonin given at the onset of reperfusion. In addition, either a non-specific melatonin receptor (MT) blocker or specific MT2 blocker was given to rats. RESULTS: Treatment with melatonin at all time points alleviated cardiac I/R injury to a similar extent, quantified by reduction in infarct size, arrhythmia score, LV dysfunction, cardiac mitochondrial dysfunction, imbalance of mitochondrial dynamics, excessive mitophagy, and a decreased Bax/Bcl2 ratio. In H9C2 cells, melatonin increased %cell viability by reducing mitochondrial dynamic imbalance and a decrease in Bax protein expression. The cardioprotective effects of melatonin were dependent on MT2 activation. CONCLUSION: Melatonin given before or after ischemia exerted equal levels of cardioprotection on the heart with I/R injury, and its beneficial effects on cardiac arrhythmias, cardiac mitochondrial function and dynamics were dependent upon the activation of MT2.
format Online
Article
Text
id pubmed-8020169
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80201692021-04-08 Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection Singhanat, Kodchanan Apaijai, Nattayaporn Jaiwongkam, Thidarat Kerdphoo, Sasiwan Chattipakorn, Siriporn C. Chattipakorn, Nipon J Adv Res Medicine INTRODUCTION: Previous studies reported the beneficial effects of pretreatment with melatonin on the heart during cardiac ischemia/reperfusion (I/R) injury. However, the effects of melatonin given after cardiac ischemia, as well as its comparative temporal effects are unknown. These include pretreatment, during ischemia, and at the onset of reperfusion. Also, the association between melatonin receptors and cardiac arrhythmias, mitochondrial function and dynamics, autophagy, and mitophagy during cardiac I/R have not been investigated. OBJECTIVES: We tested two major hypotheses in this study. Firstly, the temporal effect of melatonin administration exerts different cardioprotective efficacy during cardiac I/R. Secondly, melatonin provides cardioprotective effects via MT2 activation, leading to improvement in cardiac mitochondrial function and dynamics, reduced excessive mitophagy and autophagy, and decreased cardiac arrhythmias, resulting in improved LV function. METHODS: Male rats were subjected to cardiac I/R, and divided into 4 intervention groups: vehicle, pretreatment with melatonin, melatonin given during ischemia, and melatonin given at the onset of reperfusion. In addition, either a non-specific melatonin receptor (MT) blocker or specific MT2 blocker was given to rats. RESULTS: Treatment with melatonin at all time points alleviated cardiac I/R injury to a similar extent, quantified by reduction in infarct size, arrhythmia score, LV dysfunction, cardiac mitochondrial dysfunction, imbalance of mitochondrial dynamics, excessive mitophagy, and a decreased Bax/Bcl2 ratio. In H9C2 cells, melatonin increased %cell viability by reducing mitochondrial dynamic imbalance and a decrease in Bax protein expression. The cardioprotective effects of melatonin were dependent on MT2 activation. CONCLUSION: Melatonin given before or after ischemia exerted equal levels of cardioprotection on the heart with I/R injury, and its beneficial effects on cardiac arrhythmias, cardiac mitochondrial function and dynamics were dependent upon the activation of MT2. Elsevier 2020-09-28 /pmc/articles/PMC8020169/ /pubmed/33842003 http://dx.doi.org/10.1016/j.jare.2020.09.007 Text en © 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Medicine
Singhanat, Kodchanan
Apaijai, Nattayaporn
Jaiwongkam, Thidarat
Kerdphoo, Sasiwan
Chattipakorn, Siriporn C.
Chattipakorn, Nipon
Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title_full Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title_fullStr Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title_full_unstemmed Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title_short Melatonin as a therapy in cardiac ischemia-reperfusion injury: Potential mechanisms by which MT2 activation mediates cardioprotection
title_sort melatonin as a therapy in cardiac ischemia-reperfusion injury: potential mechanisms by which mt2 activation mediates cardioprotection
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020169/
https://www.ncbi.nlm.nih.gov/pubmed/33842003
http://dx.doi.org/10.1016/j.jare.2020.09.007
work_keys_str_mv AT singhanatkodchanan melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection
AT apaijainattayaporn melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection
AT jaiwongkamthidarat melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection
AT kerdphoosasiwan melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection
AT chattipakornsiripornc melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection
AT chattipakornnipon melatoninasatherapyincardiacischemiareperfusioninjurypotentialmechanismsbywhichmt2activationmediatescardioprotection